

October 04-06, 2018 Moscow. Russia

Yong-Xi Li, Int J Drug Dev & Res 2018, Volume 10 DOI: 10.21767/0975-9344-C1-001


## 17<sup>th</sup> Edition of International Conference and Exhibition on

## Pharmaceutics and Novel Drug Delivery Systems

## Challenge in bioanalytical methodology for long-acting delivery therapies



Medpace Bioanalytical Laboratories, USA





as examples. For such successfully developed and validated methods following US FDA and European EMA guidance, they are successfully used in clinical trial studies for their PK/PD assessments.

## **Biography**

Yong-Xi Li has completed his Postdoctoral trainings at Kansas State University, Cornell University, USA. Currently he is an Executive Director at Medpace Bioanalytical Laboratories after he served as Vice President at XenoBiotic Labs and Ricerca Bioscience. His experiences are focusing on bioanalysis: Toxicokinetic (TK), Pharmacokinetic (PK), anti-drug antibody (ADA), neutralising antibody detection (Nab) (and cell base Nab), and pharmacodynamic (PD) markers including method developments, validations, sample analysis for small molecule, protein and antibody therapies. He and his group developed many such applications by using LC-MS/MS and immunoassays (ELISA, ECL and flow cytometry). He is author, co-author of more than 150 papers, book, presentations in reputed journals, and conferences. He is also serving as an Organizing Committee Member for one of biotech conferences.

v.li@medpace.com